Valeant develops and markets a wide range of over-the-counter and prescription medicines to Australasia, Asia-Pacific, South Africa, the Americas and other international markets. In Australia, we continue to build our presence in the Consumer market through the acquisitions of well-respected brands. We do this with an ever-increasing range of known and trusted brands in several categories including consumer skincare & cosmetics, dermatology and cough and cold market segments. Our known and trusted brands like Dermaveen®, Dermadrate® Dry Skin Treatment, Dermatix® amd Pevaryl® are only sold through pharmacy, while our new brands Difflam and Duro Tuss in the cough and cold area help Australians to better health. Others like UV Tripleguard® and Reef are well known and loved by Australians. Valeant also has a core and growing ethical pharmaceutical business in Australia with products such as Efudix and Retrieve and a leading therapeutic weight management brand, Duromine.
We recently established new growth platforms in Southeast Asia and South Africa through our recent acquisition of iNova Pharmaceuticals at the end of 2011. This transaction not only transformed our operations in the Australian market, but provided us with a beachhead in both Southeast Asia and South Africa where our strategic objective is to reinforce iNova as an Asia-centric company.